Our Pipeline

Stage
Clinical Stage
Candidate
Modality & Indication
Preclinical
Phase 1
Phase 2
Candidate
TH104

MOR/KOR

Transmucosal Film:

Avoids first pass liver effect

Modality & Indication

Moderate-to-Severe Chronic Pruritis in Primary Biliary Cholangitis

Status: Phase 2
Phase 2 Ready*
Modality & Indication

Undisclosed Indication

Status: Phase 1

Phase 1
Ready*

Phase 1 Ready*

Anticipated Milestones
Anticipated Milestones
2024:

2Q: Ph1 Topline

2H: Ph2 Initiation

2025:

1H: Ph2 Topline Readout

Potential Registration Trial Initiation

Early Stage
Candidate
HER2/HER3

Platform

PD-1/ HER2/HER3

Multi-specific Knob Domain Platform

Modality & Indication

Bispecific Antibodies & ADCs for multiple solid tumors

Status: Preclinical
Preclinical
Anticipated Milestones
2024:

Pre-clinical Studies

2025:

IND enabling studies

Lead Program: TH104

TH104 prepares for Phase 2 this year, with Phase 3 readiness expected next year. This innovative pharmaceutical represents a cornerstone in our science and clinical program.

TH104 employs a unique approach by encapsulating the drug onto a proprietary transmucosal buccal film, adhering seamlessly to the mouth’s inner lining. TH104 targets both the µ-opioid receptor and the kappa opioid receptor, as well as suppresses IL-17 inflammatory cytokine expression, enhancing its therapeutic potential.

With the completion of TH104 Phase 1 pharmacokinetic trial in early 2024, we look to continue with our phase 2 proof-of-concept study in Primary Biliary Cholangitis (PBC) patients. Leveraging expertise and commitment to scientific excellence, we anticipate significant milestones in TH104’s clinical development.

Beyond liver-related disorders, TH104 shows promise in treating chronic pruritogenic conditions associated with cholestatic liver disease and other ailments like fatty and alcoholic liver disease, non-alcoholic liver disease, and certain types of hepatitis.

Chronic pruritus remains a focal point of our therapeutic endeavors. With TH104, we’re dedicated to advancing innovative solutions that alleviate suffering and enhance patients’ quality of life worldwide.